Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker NMRA
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 21,055 | $1.60 | $33.7K Sale | Form 4 ↗ |
| Aug 21, 2026 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 20,553 | $1.59 | $32.7K Sale | Form 4 ↗ |
| Aug 20, 2026 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 66,711 | $1.51 | $100.7K Sale | Form 4 ↗ |
| Aug 20, 2026 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 67,741 | $1.51 | $102.3K Sale | Form 4 ↗ |
| Aug 19, 2026 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 30,918 | $1.65 | $51.0K Sale | Form 4 ↗ |
| Aug 19, 2026 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 31,000 | $1.65 | $51.1K Sale | Form 4 ↗ |
| Aug 18, 2026 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 34,987 | $1.59 | $55.6K Sale | Form 4 ↗ |
| Aug 18, 2026 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 34,162 | $1.58 | $54.0K Sale | Form 4 ↗ |
| Aug 17, 2026 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 55,016 | $1.50 | $82.5K Sale | Form 4 ↗ |
| Aug 17, 2026 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 34,020 | $1.49 | $50.7K Sale | Form 4 ↗ |
| Aug 17, 2026 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 57,670 | $1.51 | $87.1K Sale | Form 4 ↗ |
| Feb 17, 2026 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 6,165 | $3.56 | $21.9K Sale | Form 4 ↗ |
| Feb 17, 2026 | Joshua Pinto President | NMRA Neumora Therapeutics, Inc. | Sale | 5,967 | $3.54 | $21.1K Sale | Form 4 ↗ |
| Feb 17, 2026 | Paul L. Berns See Remarks, Director | NMRA Neumora Therapeutics, Inc. | Sale | 9,819 | $3.51 | $34.5K Sale | Form 4 ↗ |
| Feb 17, 2026 | Michael Lee Milligan See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 1,436 | $3.57 | $5,127 Sale | Form 4 ↗ |
| Nov 11, 2025 | Daljit Singh Aurora See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 114,703 | $2.68 | $307.4K Sale | Form 4 ↗ |
| Oct 27, 2025 | Kristina Burow Director, 10% owner | NMRA Neumora Therapeutics, Inc. | Buy | 1.92M | $2.61 | $5.0M Buy | Form 4 ↗ |
| Oct 27, 2025 | ARCH Venture Partners XII, LLC 10% owner | NMRA Neumora Therapeutics, Inc. | Buy | 1.92M | $2.61 | $5.0M Buy | Form 4 ↗ |
| Oct 27, 2025 | ARCH Venture Partners VIII, LLC 10% owner | NMRA Neumora Therapeutics, Inc. | Buy | 1.92M | $2.61 | $5.0M Buy | Form 4 ↗ |
| Feb 18, 2025 | Paul L. Berns See Remarks, Director | NMRA Neumora Therapeutics, Inc. | Sale | 13,871 | $1.69 | $23.4K Sale | Form 4 ↗ |
| Feb 18, 2025 | Michael Lee Milligan See Remarks | NMRA Neumora Therapeutics, Inc. | Sale | 1,978 | $1.69 | $3,343 Sale | Form 4 ↗ |
| Feb 18, 2025 | Daljit Singh Aurora Chief Strategy Officer | NMRA Neumora Therapeutics, Inc. | Sale | 8,565 | $1.68 | $14.4K Sale | Form 4 ↗ |
| Feb 18, 2025 | Robert A. Lenz Head of R&D | NMRA Neumora Therapeutics, Inc. | Sale | 5,614 | $1.67 | $9,375 Sale | Form 4 ↗ |
| Feb 18, 2025 | Joshua Pinto President | NMRA Neumora Therapeutics, Inc. | Sale | 8,048 | $1.67 | $13.4K Sale | Form 4 ↗ |
| Oct 18, 2024 | Matthew K. Fust Director | NMRA Neumora Therapeutics, Inc. | Sale | 14,049 | $17.03 | $239.3K Sale | Form 4 ↗ |
| Oct 17, 2024 | Matthew K. Fust Director | NMRA Neumora Therapeutics, Inc. | Sale | 7,739 | $17.01 | $131.6K Sale | Form 4 ↗ |
| Oct 10, 2024 | Robert A. Lenz Head of R&D | NMRA Neumora Therapeutics, Inc. | Sale | 8,260 | $15.09 | $124.6K Sale | Form 4 ↗ |
| Oct 9, 2024 | Robert A. Lenz Head of R&D | NMRA Neumora Therapeutics, Inc. | Sale | 5,563 | $15.01 | $83.5K Sale | Form 4 ↗ |
28 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 7:04 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances